Amicus Therapeutics posted 2025 revenue of $634.2 million, up 20% reported and 17% at constant exchange rates, anchored by double‑digit growth in Fabry therapy Galafold ($521.7 million, +14%) and accelerating traction for Pompe regimen Pombiliti + Opfolda ($112.5 million, +60%). The company ended the year with $293.5 million in cash and equivalents, narrowed its GAAP net loss to $27.1 million, and delivered $96.8 million in non‑GAAP net income. Against that backdrop, Amicus is slated to be acquired by BioMarin in an all‑cash deal valuing the company at approximately $4.8 billion, with early termination of the HSR waiting period already granted and closing targeted for the second quarter of 2026.
The strategic question is whether BioMarin can convert Amicus’ focused rare‑disease commercial engine into a margin‑accretive growth pillar while reshaping competitive dynamics in lysosomal disorders. BioMarin brings deep global infrastructure, established payer relationships, and a portfolio historically centered on enzyme replacement therapies and ultra‑rare diseases. Amicus contributes an oral chaperone in Fabry and a next‑generation Pompe regimen that pairs a bis‑M6P enriched GAA with an enzyme stabilizer—two differentiated assets squarely within the same specialist call point. The combined footprint could compress time to access in newly launching markets, expand HCP reach across metabolic centers, and standardize evidence packages for HTAs.
This matters now because the rare‑disease market is entering a new phase of scrutiny and choice. In Fabry, the therapeutic set is broadening beyond traditional ERTs from Sanofi and Takeda; an oral option with sustained adherence and long‑term organ protection data is increasingly relevant to both patients and prescribers. In Pompe, share capture hinges on convincing payers and clinicians that functional outcomes and respiratory measures justify switching from incumbent ERTs, especially in late‑onset disease where treatment goals are stabilization rather than reversal. Amicus’ fourth‑quarter revenue step‑up and inventory build suggest it is preparing for broader country launches; under BioMarin, that ramp could accelerate, but will require disciplined pricing and outcomes contracting to withstand HTA challenges.
For Commercial leaders, the signal is consolidation as a scale strategy in orphan markets. With small and mid‑cap biotechs constrained by capital markets, large‑cap rare‑disease players are locking up cash‑flowing assets with durable exclusivity and clear specialist alignment. The $14.50 per share take‑out reflects confidence in sustained Galafold growth and a multiyear adoption curve for Pombiliti + Opfolda. For Medical Affairs, Amicus’ recent real‑world and clinical data at a major lysosomal disease congress highlight how RWE is becoming the currency for payer renewal cycles and label‑expansion narratives. Harmonizing global registries, adherence analytics for oral therapies, and longitudinal organ‑function readouts will be central to post‑deal evidence strategies.
Competitively, Sanofi’s Pompe franchise faces a more credible challenger, particularly if BioMarin deploys cross‑portfolio contracting and co‑promotion synergies. In Fabry, emerging gene therapies may eventually reset expectations, but near‑term adoption will be gated by procedure risk, durability uncertainty, and manufacturing capacity—leaving room for an oral chronic option to defend and grow share. Payers will press for step edits, switching criteria, and head‑to‑head or network meta‑analyses; the combined company’s ability to deliver consistent outcomes data across regions could become a decisive advantage.
The next 12 months will reveal whether integration planning turns Amicus’ momentum into a smoother, faster global launch cadence. The sharp question for leaders across Commercial and Medical: can BioMarin leverage scale and evidence to shift Fabry and Pompe treatment algorithms now, before the next wave of gene and substrate‑reduction competitors reframes the value discussion?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
